TGTX
TG Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$55.85
−1.52%Aug 23, 2026, 08:10 UTC
Deutsche Bank AG acquired a new stake of 235,481 shares in TG Therapeutics, Inc., valued at approximately $12.9 million, as disclosed in a Form 13F filing.
Source:Aug 3, 2026, 11:00 UTC
TG Therapeutics announced its financial results for the second quarter of 2026, reporting total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million.
Jul 7, 2026, 14:01 UTC
TG Therapeutics begins a Phase II study with Briumvi in adult patients with treatment-resistant schizophrenia.
Source:Jun 10, 2026, 14:21 UTC
TG Therapeutics announced positive phase I data for subcutaneous Briumvi in myasthenia gravis and initiated a phase II study in MG.
Source:Jun 4, 2026, 16:01 UTC
TG Therapeutics announced positive Phase I data for subcutaneous Briumvi, showing over 60% bioavailability, sustained drug exposure, and good tolerability.
Source:Jun 3, 2026, 11:30 UTC
TG Therapeutics announced positive Phase 1 trial results for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy).
Source: